Kite Pharma Inc. has augmented its T-cell receptor (TCR) platform and is making itself known in Europe via the buyout of privately held T-Cell Factory B.V. for €20 million (US$21 million) up front to the Amsterdam-based firm's shareholders, licensors and employees.